Lipopolysaccharide (LPS) is a potent stimulus for macrophage production of TNFα, IL-1 and NO. 1 Although multiple signaling pathways lead to production of these inflammatory mediators, the exact mechanisms by which LPS transduces them remain unclear. Activation of MAP kinases, including ERK1 and ERK2, as well as activation of the transcription factor NF-κB, are two signaling events initiated by LPS in macrophages. 2 One consequence of macrophage activation is the upregulation of iNOS and the subsequent release of NO from the cell. 3 Several studies have found that P2 receptor ligands influence macrophage inflammatory mediator production stimulated by LPS, suggesting a complimentary role for these receptors in LPS signal transduction. For example, LPS-treated macrophages are known to release ATP for subsequent autocrine stimulation, 4 and extracellular ATP has been shown to enhance the production of NO and TNFα in LPS-stimulated RAW 264.7 macrophages, 5 suggesting a physiological function for ATP release. Additionally, we have observed inhibitory effects of the P2 receptor ligand 2-methylthio-ATP (2-MeS-ATP) at the
INTRODUCTION
Purinergic receptors of the P2 class are cell surface receptors which are sensitive to extracellular adenine nucleotides, such as ATP and ADP. This class of receptors is divided into the P2Y family of G protein-coupled receptors and the P2X family of ligand-gated ion channels. The P2X receptors, seven of which have been cloned, are thought to possess two transmembrane domains and function as multimeric complexes. Numerous studies have suggested a role for P2 receptors in activation of macrophages by Gram-negative bacterial endotoxin (lipopolysaccharide; LPS). LPS is thought to exert its toxic effects, in large part, by inducing macrophages to release inflammatory mediators such as tumor necrosis factor α (TNFα), interleukin-1 (IL-1) and nitric oxide (NO). Although multiple signal transduction pathways are activated by LPS in macrophages, the proximal mechanisms by which LPS exerts these effects remain unclear. The current study examines the role of the P2X 7 /P2Z purinergic receptor in LPS signaling events and in nitric oxide (NO) production.
The results indicate that the P2X 7 receptor is required for maximal LPS activation of the mitogenactivated protein (MAP) kinases extracellular signal-regulated kinase (ERK)1 and ERK2, for activation of nuclear factor (NF)-κB, as well as for upregulation of the inducible form of nitric oxide synthase (iNOS). These results are fortified by our recent observation that the C-terminus of the P2X 7 receptor is homologous to conserved LPS binding domains of proteins critical to host responses to Gram-negative bacterial infection, such as LPS-binding protein (LBP) and bactericidal permeability-increasing protein (BPI). Taken together, these observations suggest that the P2X 7 receptor plays a fundamental role in LPS signal transduction and activation of macrophages, and thus may represent a therapeutic target for Gram-negative bacterial septicemia. biochemical, cellular and whole animal levels. [6] [7] [8] Our initial observation was that 2-MeS-ATP blocked a RAW 264.7 membrane-associated LPS-stimulated GTPase activity, which was enhanced by other P2 receptor ligands. 6 The P2 receptor ligand, 2-MeS-ATP, also reduced LPS-induced iNOS mRNA and protein production and NO release 7 as well as TNFα release in primary mouse macrophages. 8 Most strikingly, we showed that 2-MeS-ATP protects mice from death in response to a lethal challenge of LPS, while reducing the circulating levels of TNFα and IL-1α, but not IL-6. 8 This differential modulation of LPS-stimulated macrophage mediators suggested the influence of a P2 receptor in inhibition of selected signaling pathways.
The P2X 7 receptor has recently been cloned and was found to be identical to the previously described P2Z receptor of macrophages. 9 Like other P2X receptors, the P2X 7 receptor functions as an ion channel. The receptor is larger than other P2X family members; specifically, it has a long C-terminal tail which is thought to confer its unique activity: that of a permeabilizing pore. Prolonged pore activation can lead to cell lysis. 10 Deletion studies suggest that pore formation, but not ion channel activity, requires the C-terminal tail. 9 Blockade of the receptor with oxidized ATP (o-ATP), however, prevents both ion channel and pore activities in response to receptor ligands. 11 Upregulation of the P2X 7 receptor is associated with the maturation of macrophages. For example, resting THP-1 monocytes express relatively low levels of P2X 7 receptor mRNA; however, upon stimulation with LPS and IFN-γ, these cells upregulate P2X 7 receptor expression. 12 The time course of P2X 7 receptor upregulation correlates with TNFα and IL-1β mRNA production.
We have shown that antagonism of the P2X 7 receptor with o-ATP in RAW 264.7 cells inhibits signaling events and NO production. 13 We have demonstrated that RAW 264.7 macrophages express P2X 7 receptor mRNA by reverse transcriptase-polymerase chain reaction (rt-PCR) and subsequent sequencing of the PCR product. Additionally, cellular uptake of the fluorescent dye, YO-PRO-1, a measure of pore activity, in response to the P2X 7 -selective agonist, 3′-(O)-(4-benzoylbenzoic)-ATP (Bz-ATP), verified expression of a functional receptor. Together, the following observations indicate that the P2X 7 receptor plays a significant role in LPS-induced activation the RAW 264.7 macrophage-like cell line.
MATERIALS AND METHODS

Materials
LPS (Escherichia coli serotype O111:B4) was obtained from Sigma (St Louis, MO, USA). Rabbit polyclonal antimurine iNOS antibody was purchased from Transduction Laboratories (Lexington, KY, USA), anti-ACTIVE™ MAP kinase (ERK1/ERK2) antibody was from Promega (Madison, WI, USA), horseradish peroxidase-conjugated goat anti-rabbit IgG was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and LumiGLO™ substrates were purchased from Kirkegaard & Perry Laboratories (Gaithersburg, MD, USA). [γ-32 P]-ATP was purchased from Amersham Pharmacia Biotech. The NF-κB Binding Protein Detection System was from Gibco BRL (Gaithersburg, MD, USA). Cosmic calf serum was obtained from Hyclone (Logan, UT, USA). All other cell culture reagents were purchased from BioWhittaker (Walkersville, MD, USA). PPADS was obtained from Tocris Cookson (Langford, Bristol, UK). All other chemicals were obtained from Sigma and were the highest quality available.
Cell culture
The murine macrophage-like cell line RAW 264.7 was cultured as described previously 14 using RPMI 1640 medium supplemented with 5% cosmic calf serum. Cells were plated 18-24 h before treatment. In experiments involving o-ATP, cells were pretreated with the indicated concentrations of the antagonist for 2 h, washed with medium, and treated as indicated.
Nitric oxide assay
Nitrite concentration of RAW 264.7 medium after 20 h of cell treatment was determined by addition of one volume of Griess reagent. 15 Absorbances were read at 550 nm and were compared to a NaNO 2 standard curve.
iNOS and ERK1/ERK2 immunoblotting Cells were treated for 15 min (ERK1/ERK2) or 20 h (iNOS). Active ERK1/ERK2 and iNOS were detected by standard immunoblotting techniques using the primary antibodies anti-ACTIVE™ MAP kinase and polyclonal anti-iNOS, respectively, followed by probing with horseradish peroxidase-conjugated secondary antibody. Blots were developed with LumiGLO™ and visualized by luminography.
MTT dye reduction assay
Cell viability was assessed as described 16 by incubating cells with 1 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) for 2 h, solubilizing overnight in 20% SDS in 50% N,N-dimethylformamide LPS-stimulated signaling events and NO release in macrophages 71 (DMF) and reading absorbances at 595 nm. Treatment of cells with sterile de-ionized water served as a control for complete cell death.
NF-κB electrophoretic mobility shift assay
The NF-κB Binding Protein Detection System was used according to the manufacturer's instructions. Cells were treated for 1 h and nuclear proteins extracted. Nuclear extract protein (5 µg) was incubated with 10 5 cpm of oligonucleotide at room temperature for 20 min. DNA/protein complexes were resolved on a 6% nondenaturing polyacrylamide gel and visualized by autoradiography.
RESULTS AND DISCUSSION
Because a hallmark of P2X 7 /P2Z receptor activation is cell lysis, we assessed the ability of several P2 receptor agonists to induce RAW 264.7 cell death, and the ability of o-ATP to inhibit this effect. The P2 receptor agonists, Bz-ATP (500 µM), 2-MeS-ATP (1 mM), and the nonhydrolyzable ATP analog, ATP-γS (1 mM), reduced cell viability by about 95% after a 20 h treatment. This effect was dose-dependently attenuated by o-ATP pretreatment, indicating that o-ATP exerts its inhibitory effects, at least in part, by antagonizing the P2X 7 receptor. Treatment with o-ATP alone had no effect on cell viability at the concentrations used.
LPS effects a dose-dependent increase in macrophage expression of iNOS and subsequent release of NO. 3 Pretreatment with o-ATP inhibited iNOS upregulation in RAW 264.7 cells dose-dependently in response to 20 h treatments with LPS at 10 ng/ml, 100 ng/ml and 1000 ng/ml (Fig. 1A) . Not unexpectedly, there was a concurrent reduction in the amount of nitrite released from these cells (Fig. 1B) . Co-treatment with the P2X receptor antagonist, pyridoxal phosphate-6-azophenyl-2′,4′-disulfonic acid (PPADS), also inhibited LPS upregulation of iNOS dosedependently and protected against Bz-ATP-induced cell death.
Another characteristic of LPS signal transduction is the activation of multiple MAPK isoforms. 2 Pretreatment with o-ATP inhibited ERK1/ERK2 activation in RAW 264.7 cells stimulated for 15 min with LPS at 10 ng/ml, 100 ng/ml and 1000 ng/ml (Fig. 1C) . Pretreatment with o-ATP did not, however, affect the ability of 1 µM PMA to activate ERK1/ERK2, indicating that the cells were viable and able to respond to other stimuli. Furthermore, o-ATP pretreatment did not block ERK1/ERK2 activation by UTP, a selective ligand for the P2Y 2 receptor, again suggesting selective blockade of the P2X 7 receptor.
Many LPS-responsive genes, including iNOS, TNFα and IL-1β, contain recognition sequences for the binding of the κB/rel transcription factor family 2 and NF-κB activation is required for maximal iNOS upregulation in RAW 264.7 macrophages. 17, 18 Furthermore, NF-κB can be activated by ATP and Bz-ATP in microglial cells and this activity can be blocked by o-ATP, 19 suggesting P2X 7 receptor involvement. Because we observed a reduction in iNOS production after o-ATP pretreatment, we suspected that o-ATP would also reduce LPS-stimulated NF-κB activation. Indeed, o-ATP pretreatment dose- washed twice with fresh medium, and treated with control, 10 ng/ml, 100 ng/ml, or 1000 ng/ml LPS for 20 h at 37°C. Nitrite levels in the medium were determined by addition of the Griess reagent and measurement of the absorbance at 550 nm. The results are presented as the mean ± SE of triplicate measurements, and similar results were obtained from five individual experiments. (C) RAW 264.7 cells were incubated with control medium, 250 µM o-ATP, or 500 µM o-ATP for 2 h, washed twice with fresh medium, and treated with control, LPS (10 ng/ml, 100 ng/ml, or 1000 ng/ml), or 1 µM PMA for 15 min at 37°C. ERK1/ERK2 activation was determined by immunoblotting with an antibody specific for the threonine and tyrosine phosphorylated (active) form of ERK1/ERK2. Similar results were obtained in three separate experiments. This figure has been adapted with permission from Hu et al. 13 dependently reduced NF-κB DNA binding activity in response to a 1 h treatment with LPS at 10 ng/ml, 100 ng/ml and 1000 ng/ml.
In summary, our results indicate that LPS stimulation of ERK1/ERK2, NF-κB and NO production are regulated, at least in part, by the P2X 7 receptor. Based on these findings, we propose a model of LPS activation which includes the P2X 7 receptor as a central component (Fig. 2) .
Intriguingly, we have observed that the P2X 7 receptor possesses at its C-terminus a consensus site for LPS binding. Sequence alignment of this region with the LPS-binding domains of proteins, critical for defense against bacterial infection, reveals striking homology. These proteins include the acute phase serum protein, lipopolysaccharide-binding protein (LBP) as well as the polymorphonuclear neutrophil antibiotic protein, bactericidal permeability-increasing protein (BPI). Preliminary in vitro studies utilizing synthetic peptides indicate that LPS binds to the P2X 7 receptor putative LPS-binding domain. Furthermore, LPS-stimulated ERK1/ERK2 activation, as well as inhibitor of κB (IκB)α degradation, in RAW 264.7 cells, are dose-dependently reduced by synthetic peptides of the P2X 7 receptor putative LPSbinding domain. This inhibition is also observed with a peptide corresponding to the LPS-binding domain of LBP, but is not seem with a control peptide. This activity suggests that the domain can compete with cellular receptors for binding of LPS. Taken together, these recent observations are highly suggestive of a role for the P2X 7 receptor in LPS signaling in macrophages and may provide a target for therapeutic strategies for endotoxic shock.
